Quarterly report [Sections 13 or 15(d)]

Organization and Business (Details)

v3.25.3
Organization and Business (Details)
store in Thousands, test in Millions
 3 Months Ended 9 Months Ended
Sep. 22, 2025
entity
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
licensedCompound
country
test
store
inhibitor
Sep. 30, 2024
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of lab entities filed for Chapter 11 reorganization | entity 3        
Number of licensed compounds | licensedCompound       2  
Number of inhibitors | inhibitor       2  
General and administration   $ 4,635,000 $ 6,573,000 $ 13,351,000 $ 20,805,000
DNA Expand          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of countries whole genome sequencing tests were obtained from | country       130  
Number of ancestry single nucleotide polymorphisms based tests equivalent | test       150  
Equivir          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of FDM retail stores distributed in | store       40  
BE-Smart License Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
General and administration       $ 0 $ 200,000